Core Viewpoint - Large-cap biotech stocks are considered resilient to disruption risks typically faced by tech companies, primarily due to their long drug approval processes and established product portfolios [1][2] Group 1: Biotech Sector Resilience - Companies like Amgen and AbbVie are highlighted for their ability to navigate revenue erosion through broad product portfolios and multi-year pipeline replacements [1] - The FDA approval process, which can take a decade, provides a structural time buffer that protects biotech firms from rapid obsolescence [1] - Year-to-date performance shows Amgen up 16% and Gilead up 21% in 2026, significantly outperforming the iShares Biotechnology ETF, which is up approximately 3% [1] Group 2: Disruption Mechanisms - While biotech firms are insulated from AI-driven disruption, they face challenges such as patent cliffs, biosimilar competition, and government drug pricing reforms [1] - AbbVie’s Humira lost exclusivity, leading to a revenue drop of about 50% in two years, highlighting the risks associated with patent cliffs [1] - Amgen's revenue from Enbrel fell 48% in Q4 2025 due to biosimilar competition and Medicare redesign, indicating structural revenue erosion [1] Group 3: Company-Specific Insights - Gilead's ASCENT-07 trial for Trodelvy missed its primary endpoint, demonstrating how clinical trial failures can significantly impact pipeline value [2] - Eli Lilly's stock has appreciated approximately 416% over five years, driven by the success of its GLP-1 products, but it is down 6% year-to-date in 2026 [2] - Biogen's revenue is expected to decline mid-single digits in 2026, with its MS franchise down 14% in Q4 2025, reflecting a different risk profile compared to other biotech firms [2] Group 4: Evaluating Biotech Stocks - Investors should assess biotech stocks based on three questions: the percentage of revenue from products with patent protection beyond five years, the presence of at least two Phase 3 pipeline products, and the strength of the balance sheet to support pipeline investments [2] - Amgen's CEO expressed confidence in the company's broad portfolio and innovative therapies, indicating a path for sustained long-term growth [2] - Understanding the specific types of disruption, such as patent cliffs and pricing reform, is crucial for investors to navigate volatility in the biotech sector [2]

Biogen FY Conference Summary Company Overview - **Company**: Biogen (NasdaqGS:BIIB) - **Event**: TD Cowen's 46th Annual Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Company Focus - Biogen is in a phase of rebuilding and expanding its portfolio, with a focus on late-stage pipeline development, currently having **10 Phase 3 programs** underway, with the first results expected this year [1][2] - The company has reduced R&D spending by **25%** over the past three years while increasing productivity [2] Revenue and Growth Outlook - Biogen anticipates a **mid-single digit percentage decline** in revenue for 2026, but is optimistic about returning to growth due to new product launches and a strong late-stage pipeline [4] - The company has launched four growth products in the last three years, including LEQEMBI and QALSODY, which have outpaced declines in the MS portfolio [4][5] Product Pipeline and Launches - Upcoming product launches include: - **Felzartamab** for lupus - **Salanersen**, a successor to SPINRAZA - **Zorevunersen** for Dravet syndrome - Positive results from these launches could significantly enhance growth [5] Business Development Strategy - Biogen is cautious with M&A, indicating that replacing **$1 billion** of after-tax profit would require **$15 billion-$20 billion**, which is beyond its current capacity [7] - The focus is on early-stage assets with promising Phase 3 results to complement the existing pipeline [8] LEQEMBI Launch Insights - The launch of LEQEMBI is described as complex, requiring significant adjustments in physician practices, including managing infusion beds and patient monitoring [10] - Reimbursement for LEQEMBI has not been a major issue, which has helped build physician confidence [10][11] - The introduction of blood-based diagnostics has improved patient triage and increased the eligible patient pool for treatment [12][13] Future Trials and Research - The **AHEAD 3-45 trial** is expected to provide critical insights into early Alzheimer's treatment, potentially preventing the onset of symptoms by targeting amyloid buildup [20][22] - The trial aims to determine the incidence of ARIA (Amyloid-related imaging abnormalities) and the long-term effects of early treatment [21][24] Other Product Developments - **SPINRAZA** is set for a milestone with a PDUFA for high-dose approval, which could shift competitive dynamics in the SMA field [28] - **Salanersen** is being developed to address intrathecal fatigue, with promising early results in children previously treated with gene therapy [32] Multiple Sclerosis Portfolio - Biogen expects a **mid-teens decline** in its MS franchise, primarily due to the aging product portfolio and competition from biosimilars [39] - The company is focusing on maintaining market share through patient support services and effective management of existing therapies [43][44] Conclusion - Biogen is strategically positioned to navigate challenges in the biotech landscape with a robust pipeline and a focus on innovative therapies, while also managing the complexities of product launches and market dynamics. The company is optimistic about future growth driven by new product introductions and ongoing clinical trials.

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year on both reported and constant currency basis [1][3] Financial Performance - The company achieved nearly $1 billion in revenue from its products LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue, partially offset by growth in other areas [3] Market Reaction - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus of $1.59, and revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although down 7% year-over-year [1][3] Financial Performance - The company generated nearly $1 billion in revenue from its drugs LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, reflecting strong execution and financial discipline [2] - For fiscal 2026, Biogen expects earnings between $15.25 and $16.25 per share, above the consensus estimate of $14.92, but anticipates a mid-single-digit revenue decline compared to 2025 due to expected declines in Multiple Sclerosis product revenue [3] Stock Performance and Analyst Ratings - Following the earnings announcement, Biogen shares fell 0.9% to $199.40 in pre-market trading [3] - Analysts have adjusted their price targets for Biogen, with Piper Sandler maintaining a Neutral rating and raising the target from $157 to $177, HC Wainwright & Co. maintaining a Buy rating and increasing the target from $194 to $228, and Wedbush maintaining a Neutral rating with a target increase from $178 to $187 [4]

Core Viewpoint - Biogen Inc. reported stronger-than-expected fourth-quarter 2025 results, leading to a more than 3% increase in shares, and provided an optimistic profit outlook for 2026 [1] Financial Performance - Adjusted earnings per share for Q4 2025 were $1.99, exceeding the analyst consensus of $1.61 [1] - Revenue for the quarter was $2.28 billion, surpassing expectations of $2.21 billion, although it represented a 7% decline year over year [1] Growth Products - Growth products showed positive momentum, with revenue increasing by 6% year over year in the quarter [2] - Global in-market sales of LEQEMBI reached approximately $134 million, marking a 54% year-over-year increase [2] - ZURZUVAE generated about $66 million in revenue, indicating strong demand growth [2] - SKYCLARYS expanded its global patient base by roughly 30% in 2025 [2] 2026 Outlook - For fiscal 2026, Biogen forecasts adjusted earnings per share in the range of $15.25 to $16.25, above the analyst consensus of $14.92 [3] - The company anticipates total revenue to decline by a mid-single-digit percentage compared to 2025, with expected declines in multiple sclerosis products, excluding VUMERITY, partially offset by growth in newer therapies [3]

February 6, 2026 Q4 AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE FORWARD-LOOKING STATEMENTS This presentation and discussions during this conference call contain forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; ...

January 12, 2026 DELIVERING THE NEW BIOGEN: THE NEXT CHAPTER OF INNOVATION AND GROWTH CHRISTOPHER A. VIEHBACHER PRESIDENT AND CHIEF EXECUTIVE OFFICER FORWARD-LOOKING STATEMENTS This presentation and discussions during this webcast contain forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentatio ...

Core Insights - Biogen Inc. is a leading biotechnology company focused on developing treatments for neurological diseases, particularly Alzheimer's disease, in collaboration with Eisai Co., Ltd. [1][6] - UBS has set a price target of $185 for Biogen, indicating optimism about the company's growth potential in the Alzheimer's treatment market [2] - The acceptance of the Biologics License Application for LEQEMBI's subcutaneous formulation in China is a significant milestone that could enhance Biogen's market presence in Asia [3][6] Financial Performance - Biogen's stock has shown resilience with a 15.1% increase in 2025, driven by the successful launch of LEQEMBI and a 29.9% increase in sales for Skyclarys, which reached $132.9 million in the third quarter [4][6] - Currently, Biogen's stock is trading at $182.61, reflecting a 4.57% increase, with fluctuations between $174.30 and $182.97 [5] - Over the past year, Biogen's stock reached a high of $185.17 and a low of $110.04, with a market capitalization of approximately $26.79 billion [5]

Core Points - The meeting aims to discuss Eisai's value creation initiatives and gather feedback for future planning [1] - Eisai emphasizes the social impact of its product LEQEMBI and its contributions to dementia initiatives, which enhance the company's competitiveness [2] Group 1 - The purpose of the Opinion Exchange meeting is to utilize feedback for improving management and future value creation reports [1] - Eisai's initiatives in the dementia area are highlighted as a key source of competitiveness, as detailed in the Value Creation Report 2025 [2] - The company focuses on non-financial capital, including R&D promotion, brand strengthening, and employee engagement, to enhance corporate value [2]

Core Insights - LEQEMBI IQLIK, if approved, would be the first anti-amyloid treatment allowing at-home injections from the start of therapy for Alzheimer's disease [1][5] - The FDA has received a Supplemental Biologics License Application (sBLA) for LEQEMBI IQLIK, which is indicated for early Alzheimer's disease [1][5] - The sBLA is supported by data showing that subcutaneous administration of lecanemab is as effective as intravenous dosing [2][3] Group 1: Product Development and Approval - Eisai has completed the rolling submission of the sBLA for LEQEMBI IQLIK to the FDA, which has granted Fast Track Status [1] - The sBLA includes data from Phase 3 studies demonstrating that a 500 mg weekly subcutaneous dose provides equivalent exposure and benefits compared to bi-weekly intravenous administration [2] - If approved, the autoinjector would allow patients to choose between subcutaneous and intravenous administration throughout their treatment [3] Group 2: Mechanism of Action - LEQEMBI targets both protofibrils and amyloid plaques, which are key contributors to Alzheimer's disease progression [4] - Protofibrils are considered the most toxic form of amyloid-beta and are believed to cause significant neuronal damage [6] Group 3: Market Presence - LEQEMBI is currently approved in 51 countries and regions and is under regulatory review in 9 additional countries [5][29] - The U.S. FDA approved LEQEMBI IQLIK for weekly subcutaneous maintenance dosing in August 2025, following an 18-month intravenous treatment [5][30] Group 4: Safety Profile - The safety profile of LEQEMBI IQLIK is similar to that of the intravenous formulation, with a low incidence of systemic injection-related reactions [2][29] - Common adverse reactions include infusion-related reactions (26% with LEQEMBI vs. 7% with placebo) and amyloid-related imaging abnormalities (ARIA) [29]